All the latest hires in our weekly column.
Horizon Discovery has appointed to its scientific advisory board three experts in CRISPR (clustered regularly interspaced short palindromic repeats) technology, a gene editing tool.
Emmanuelle Charpentier (pictured), Keith Joung and Feng Zhang will join the life sciences tools company as gene editing advisors.
Charpentier is the current head of the Department of Regulation in Infection Biology at the Helmholtz Centre for Infection Research in Braunschweig and Hannover Medical School. She is known for her work on bacterial immunity and uncovering key functional components of the bacterial CRISPR-Cas9 system.
Joung is Associate Chief of Pathology for Research at Massachusetts General Hospital and is an Associate Professor of Pathology at Harvard Medical School. He has worked on methods for targeted genome editing using engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9.
Zhang is currently serving as W.M. Keck Career Development Professor at the Massachusetts Institute of Technology (MIT). He engineered the CRISPR-Cas9 system for genome editing in mammalian cells, as published in Science in 2013.
Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Recipharm, Catalent, INC and PRA completed eye-catching IPOs in 2014. Which firms are likely follow suit in 2015?
Catering for low value, high volume customers as well as the growing number of firms developing complex...
Clinverse, Intertek and inVentiv are among the pharma services companies announcing new staff this week.